1.0¶¶Òõ¶ÌÊÓƵmaster/author/master/Mick Fellows, PhD | ¶¶Òõ¶ÌÊÓƵrich600338<blockquote class="wp-embedded-content" data-secret="0gvaZ3lN8k"><a href="/profile/dr-mick-fellows/">Mick Fellows, PhD</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="/profile/dr-mick-fellows/embed/#?secret=0gvaZ3lN8k" width="600" height="338" title="“Mick Fellows, PhD” — ¶¶Òõ¶ÌÊÓƵ" data-secret="0gvaZ3lN8k" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script>
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
</script>
Dr Mick Fellows is the Director of CVRM Cell Therapy Safety at AstraZeneca in Cambridge UK. He earned his Ph.D in Pharmacology and Toxicology investigating topoisomerase II inhibition at Liverpool University. In the mid 1980’s Mick joined Covance, where he developed and study directed a range of in vitro and in vivo genetox assays, becoming...